Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Markus Pfirrmann, Stefan W. Krause et al.|Leukemia|2017Cited by 339
In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalentMichele Baccarani, Francesco Passamonti, Ilaria Iacobucci et al.|Leukemia|2019Cited by 9